Adjuvant chemotherapy for non-small cell lung cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the late 1970s and early 1980s, the Lung Cancer Study Group conducted a series of adjuvant chemotherapy trials in patients with resected non-small cell lung cancer. Although some of these trials yielded modest survival benefit, the length of improved survival essentially equaled the time spent receiving chemotherapy. Consequently, few physicians routinely employ postoperative chemotherapy in spite of its theoretical appeal. Possible explanations for the failure of adjuvant chemotherapy to provide meaningful prolongation of survival in non-small cell lung cancer include lack of effective chemotherapy, incorrect chemotherapy regimen, inadequate dose intensity, and possibly inadequate trial design. Future postoperative adjuvant trials should focus on treating patients with resected early stage lesions (T1N1, T2N1, T2N0). What role, if any, newer antineoplastic agents will play in the postoperative setting remains to be determined. Neoadjuvant induction chemotherapy may well prove to be a superior treatment strategy and deserves further investigation.

Original languageEnglish (US)
JournalChest
Volume106
Issue number6 SUPPL.
StatePublished - 1994

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Induction Chemotherapy
Antineoplastic Agents
Lung Neoplasms
Physicians
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Adjuvant chemotherapy for non-small cell lung cancer. / Johnson, D. H.

In: Chest, Vol. 106, No. 6 SUPPL., 1994.

Research output: Contribution to journalArticle

@article{c07d954fa75346cb9cceabb42c998a4c,
title = "Adjuvant chemotherapy for non-small cell lung cancer",
abstract = "In the late 1970s and early 1980s, the Lung Cancer Study Group conducted a series of adjuvant chemotherapy trials in patients with resected non-small cell lung cancer. Although some of these trials yielded modest survival benefit, the length of improved survival essentially equaled the time spent receiving chemotherapy. Consequently, few physicians routinely employ postoperative chemotherapy in spite of its theoretical appeal. Possible explanations for the failure of adjuvant chemotherapy to provide meaningful prolongation of survival in non-small cell lung cancer include lack of effective chemotherapy, incorrect chemotherapy regimen, inadequate dose intensity, and possibly inadequate trial design. Future postoperative adjuvant trials should focus on treating patients with resected early stage lesions (T1N1, T2N1, T2N0). What role, if any, newer antineoplastic agents will play in the postoperative setting remains to be determined. Neoadjuvant induction chemotherapy may well prove to be a superior treatment strategy and deserves further investigation.",
author = "Johnson, {D. H.}",
year = "1994",
language = "English (US)",
volume = "106",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Adjuvant chemotherapy for non-small cell lung cancer

AU - Johnson, D. H.

PY - 1994

Y1 - 1994

N2 - In the late 1970s and early 1980s, the Lung Cancer Study Group conducted a series of adjuvant chemotherapy trials in patients with resected non-small cell lung cancer. Although some of these trials yielded modest survival benefit, the length of improved survival essentially equaled the time spent receiving chemotherapy. Consequently, few physicians routinely employ postoperative chemotherapy in spite of its theoretical appeal. Possible explanations for the failure of adjuvant chemotherapy to provide meaningful prolongation of survival in non-small cell lung cancer include lack of effective chemotherapy, incorrect chemotherapy regimen, inadequate dose intensity, and possibly inadequate trial design. Future postoperative adjuvant trials should focus on treating patients with resected early stage lesions (T1N1, T2N1, T2N0). What role, if any, newer antineoplastic agents will play in the postoperative setting remains to be determined. Neoadjuvant induction chemotherapy may well prove to be a superior treatment strategy and deserves further investigation.

AB - In the late 1970s and early 1980s, the Lung Cancer Study Group conducted a series of adjuvant chemotherapy trials in patients with resected non-small cell lung cancer. Although some of these trials yielded modest survival benefit, the length of improved survival essentially equaled the time spent receiving chemotherapy. Consequently, few physicians routinely employ postoperative chemotherapy in spite of its theoretical appeal. Possible explanations for the failure of adjuvant chemotherapy to provide meaningful prolongation of survival in non-small cell lung cancer include lack of effective chemotherapy, incorrect chemotherapy regimen, inadequate dose intensity, and possibly inadequate trial design. Future postoperative adjuvant trials should focus on treating patients with resected early stage lesions (T1N1, T2N1, T2N0). What role, if any, newer antineoplastic agents will play in the postoperative setting remains to be determined. Neoadjuvant induction chemotherapy may well prove to be a superior treatment strategy and deserves further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0028076251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028076251&partnerID=8YFLogxK

M3 - Article

C2 - 7988252

AN - SCOPUS:0028076251

VL - 106

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6 SUPPL.

ER -